Noom Med with Smart Rx , in partnership with Waltz Health, drives significant ROI for employers who wish to cover GLP-1s as a supplemental benefit such that the payer can choose the level of financial assistance they will provide Noom Weight with GLP-1 Rx delivers a proven obesity program and employee-pay access to affordable GLP-1s for employers who choose not to cover GLP-1s today New York, NY October 21, 2024 Noom, the leading digital healthcare company committed to chronic disease prevention and empowering people to live better longer, is tackling the problem of GLP-1 availability, accessibility and inflated costs head-on by launching two distinct enterprise solutions that reduce obesity management costs while enabling access to life-changing medications: Noom Med with Smart Rx in partnership with Waltz Health and Noom Weight with GLP-1 Rx

Step 1 Eligibility Pre-Screen Youll provide: BMI Age Basic contraindication check Takes about 2 minutes and provides immediate feedback if youre not a candidate
People with higher proportions of visceral fat, which is more metabolically active and responsive to hormonal signals, often see more dramatic early changes than those carrying primarily subcutaneous fat

Protocol 1: standard tirzepatide protocol Goal: Achieve 15-20% body weight reduction over 6-12 months Dose escalation: Weeks 1-4: 2.5mg subcutaneous injection once weekly Weeks 5-8: 5mg once weekly Weeks 9-12: 7.5mg once weekly (optional, can skip to 10mg) Weeks 13-16: 10mg once weekly Weeks 17-20: 12.5mg once weekly Week 21+: 15mg once weekly maintenance Administration: Inject subcutaneously in abdomen, thigh, or upper arm Rotate injection sites to prevent injection site reactions Best administered on the same day each week Store properly per tirzepatide storage requirements Nutritional support: Minimum 100-120g protein daily (see tirzepatide diet planning ) Avoid high-fat, greasy foods during escalation (check foods to avoid list ) Stay hydrated, minimum 64oz water daily Consider targeted supplementation including multivitamins, omega-3s, and B12 Expected timeline: Weeks 1-4: Appetite suppression begins, 1-3% weight loss Weeks 5-12: Noticeable results, 5-8% weight loss Weeks 13-24: Significant changes, 10-15% weight loss Weeks 25-52: Approaching maximum benefit, 15-20%+ weight loss Protocol 2: retatrutide research protocol Goal: Achieve 20-28% body weight reduction over 6-12 months Dose escalation: Weeks 1-4: 1mg subcutaneous injection once weekly Weeks 5-8: 2mg once weekly Weeks 9-12: 4mg once weekly Weeks 13-16: 8mg once weekly Week 17+: 12mg once weekly maintenance Administration: Inject subcutaneously following standard retatrutide injection technique Optimal injection sites described in the retatrutide injection site guide Store refrigerated, reconstituted vials have limited stability (see retatrutide shelf life ) Reconstitute with bacteriostatic water per reconstitution chart Important monitoring: Track resting heart rate weekly (the glucagon receptor can elevate HR) Monitor liver enzymes if MASLD is present Track body composition changes, not just scale weight Assess GI tolerance at each dose increase, slow escalation if needed Expected timeline: Weeks 1-4: Mild appetite effects at initiation dose Weeks 5-12: Progressive appetite suppression, 5-10% weight loss Weeks 13-24: Significant metabolic effects, 12-18% weight loss Weeks 25-48: Approaching maximum benefit, 20-28%+ weight loss Protocol 3: transitioning from tirzepatide to retatrutide Goal: Safely switch between compounds while maintaining weight loss momentum This protocol is specifically for researchers who have been on tirzepatide and want to transition to retatrutide, typically because of a plateau or desire for additional metabolic benefits
